Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 107

1.

Auditory System Target Engagement During Plasticity-Based Interventions in Schizophrenia: A Focus on Modulation of N-Methyl-D-Aspartate-Type Glutamate Receptor Function.

Kantrowitz JT, Swerdlow NR, Dunn W, Vinogradov S.

Biol Psychiatry Cogn Neurosci Neuroimaging. 2018 Feb 22. pii: S2451-9022(18)30045-4. doi: 10.1016/j.bpsc.2018.02.002. [Epub ahead of print] Review.

PMID:
29656951
2.

N-methyl-d-aspartate-type glutamate receptor modulators and related medications for the enhancement of auditory system plasticity in schizophrenia.

Kantrowitz JT.

Schizophr Res. 2018 Feb 17. pii: S0920-9964(18)30051-3. doi: 10.1016/j.schres.2018.02.003. [Epub ahead of print]

PMID:
29459050
3.

Genome-Wide Gene Expression Changes in the Normal-Appearing Airway during the Evolution of Smoking-Associated Lung Adenocarcinoma.

Kantrowitz J, Sinjab A, Xu L, McDowell TL, Sivakumar S, Lang W, Nunomura-Nakamura S, Fukuoka J, Nemer G, Darwiche N, Chami H, Tfayli A, Wistuba II, Scheet P, Fujimoto J, Spira AE, Kadara H.

Cancer Prev Res (Phila). 2018 Apr;11(4):237-248. doi: 10.1158/1940-6207.CAPR-17-0295. Epub 2018 Jan 30.

PMID:
29382653
4.

Hippocampal dysfunction in the pathophysiology of schizophrenia: a selective review and hypothesis for early detection and intervention.

Lieberman JA, Girgis RR, Brucato G, Moore H, Provenzano F, Kegeles L, Javitt D, Kantrowitz J, Wall MM, Corcoran CM, Schobel SA, Small SA.

Mol Psychiatry. 2018 Jan 9. doi: 10.1038/mp.2017.249. [Epub ahead of print]

PMID:
29311665
5.

Utility of Imaging-Based Biomarkers for Glutamate-Targeted Drug Development in Psychotic Disorders: A Randomized Clinical Trial.

Javitt DC, Carter CS, Krystal JH, Kantrowitz JT, Girgis RR, Kegeles LS, Ragland JD, Maddock RJ, Lesh TA, Tanase C, Corlett PR, Rothman DL, Mason G, Qiu M, Robinson J, Potter WZ, Carlson M, Wall MM, Choo TH, Grinband J, Lieberman JA.

JAMA Psychiatry. 2018 Jan 1;75(1):11-19. doi: 10.1001/jamapsychiatry.2017.3572.

PMID:
29167877
6.

A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Tocilizumab, An Interleukin-6 Receptor Antibody, For Residual Symptoms in Schizophrenia.

Girgis RR, Ciarleglio A, Choo T, Haynes G, Bathon JM, Cremers S, Kantrowitz JT, Lieberman JA, Brown AS.

Neuropsychopharmacology. 2018 May;43(6):1317-1323. doi: 10.1038/npp.2017.258. Epub 2017 Nov 1.

PMID:
29090685
7.

Reflections On Mortality: A Patient Faces Death.

Kantrowitz JL.

J Am Psychoanal Assoc. 2017 Aug;65(4):673-686. doi: 10.1177/0003065117721162. No abstract available.

PMID:
28899171
8.

A tale of two sites: Differential impairment of frequency and duration mismatch negativity across a primarily inpatient versus a primarily outpatient site in schizophrenia.

Lee M, Sehatpour P, Dias EC, Silipo GS, Kantrowitz JT, Martinez AM, Javitt DC.

Schizophr Res. 2018 Jan;191:10-17. doi: 10.1016/j.schres.2017.07.032. Epub 2017 Aug 2.

PMID:
28779851
9.

Mismatch negativity as a biomarker of theta band oscillatory dysfunction in schizophrenia.

Javitt DC, Lee M, Kantrowitz JT, Martinez A.

Schizophr Res. 2018 Jan;191:51-60. doi: 10.1016/j.schres.2017.06.023. Epub 2017 Jun 28.

PMID:
28666633
10.

Neurophysiological Effects of Bitopertin in Schizophrenia.

Kantrowitz JT, Nolan KA, Epstein ML, Lehrfeld N, Shope C, Petkova E, Javitt DC.

J Clin Psychopharmacol. 2017 Aug;37(4):447-451. doi: 10.1097/JCP.0000000000000722.

PMID:
28590364
11.

Mismatch negativity (MMN) to spatial deviants and behavioral spatial discrimination ability in the etiology of auditory verbal hallucinations and thought disorder in schizophrenia.

Perrin MA, Kantrowitz JT, Silipo G, Dias E, Jabado O, Javitt DC.

Schizophr Res. 2018 Jan;191:140-147. doi: 10.1016/j.schres.2017.05.012. Epub 2017 May 19.

PMID:
28532686
12.

Managing Negative Symptoms of Schizophrenia: How Far Have We Come?

Kantrowitz JT.

CNS Drugs. 2017 May;31(5):373-388. doi: 10.1007/s40263-017-0428-x. Review.

PMID:
28397113
13.

Improvement in mismatch negativity generation during d-serine treatment in schizophrenia: Correlation with symptoms.

Kantrowitz JT, Epstein ML, Lee M, Lehrfeld N, Nolan KA, Shope C, Petkova E, Silipo G, Javitt DC.

Schizophr Res. 2018 Jan;191:70-79. doi: 10.1016/j.schres.2017.02.027. Epub 2017 Mar 18.

PMID:
28318835
14.

Characterization of the Anti-PD-1 Antibody REGN2810 and Its Antitumor Activity in Human PD-1 Knock-In Mice.

Burova E, Hermann A, Waite J, Potocky T, Lai V, Hong S, Liu M, Allbritton O, Woodruff A, Wu Q, D'Orvilliers A, Garnova E, Rafique A, Poueymirou W, Martin J, Huang T, Skokos D, Kantrowitz J, Popke J, Mohrs M, MacDonald D, Ioffe E, Olson W, Lowy I, Murphy A, Thurston G.

Mol Cancer Ther. 2017 May;16(5):861-870. doi: 10.1158/1535-7163.MCT-16-0665. Epub 2017 Mar 6.

15.

Neural mechanisms of mismatch negativity dysfunction in schizophrenia.

Lee M, Sehatpour P, Hoptman MJ, Lakatos P, Dias EC, Kantrowitz JT, Martinez AM, Javitt DC.

Mol Psychiatry. 2017 Nov;22(11):1585-1593. doi: 10.1038/mp.2017.3. Epub 2017 Feb 7.

16.

Sleep disturbances in individuals at clinical high risk for psychosis.

Poe SL, Brucato G, Bruno N, Arndt LY, Ben-David S, Gill KE, Colibazzi T, Kantrowitz JT, Corcoran CM, Girgis RR.

Psychiatry Res. 2017 Mar;249:240-243. doi: 10.1016/j.psychres.2016.12.029. Epub 2016 Dec 23.

17.

Neurophysiological mechanisms of cortical plasticity impairments in schizophrenia and modulation by the NMDA receptor agonist D-serine.

Kantrowitz JT, Epstein ML, Beggel O, Rohrig S, Lehrfeld JM, Revheim N, Lehrfeld NP, Reep J, Parker E, Silipo G, Ahissar M, Javitt DC.

Brain. 2016 Dec;139(Pt 12):3281-3295.

18.

d-Cycloserine, an NMDA Glutamate Receptor Glycine Site Partial Agonist, Induces Acute Increases in Brain Glutamate Plus Glutamine and GABA Comparable to Ketamine.

Kantrowitz JT, Milak MS, Mao X, Shungu DC, Mann JJ.

Am J Psychiatry. 2016 Dec 1;173(12):1241-1242. No abstract available.

PMID:
27903101
19.

Nondestructive cryomicro-CT imaging enables structural and molecular analysis of human lung tissue.

Vasilescu DM, Phillion AB, Tanabe N, Kinose D, Paige DF, Kantrowitz JJ, Liu G, Liu H, Fishbane N, Verleden SE, Vanaudenaerde BM, Lenburg M, Stevenson CS, Spira A, Cooper JD, Hackett TL, Hogg JC.

J Appl Physiol (1985). 2017 Jan 1;122(1):161-169. doi: 10.1152/japplphysiol.00838.2016. Epub 2016 Nov 17.

20.

Dr Kantrowitz and Colleagues Reply.

Kantrowitz JT, Medalia A, Keefe RS, Harvey PD, Bruder G, Barch DM, Choo T, Lee S, Lieberman JA.

J Clin Psychiatry. 2016 Oct;77(10):e1353. doi: 10.4088/JCP.16lr10887a. No abstract available.

21.

Dr Kantrowitz and Colleagues Reply.

Kantrowitz JT, Halberstam B, Gangwisch J.

J Clin Psychiatry. 2016 Aug;77(8):e1008. doi: 10.4088/JCP.15lr10272a. No abstract available.

22.

Appreciation of the Importance of the Patient-Analyst "Match".

Kantrowitz JL.

Psychiatry. 2016 Spring;79(1):23-8. doi: 10.1080/00332747.2016.1151316. No abstract available.

PMID:
27187509
23.

A Multicenter, Rater-Blinded, Randomized Controlled Study of Auditory Processing-Focused Cognitive Remediation Combined With Open-Label Lurasidone in Patients With Schizophrenia and Schizoaffective Disorder.

Kantrowitz JT, Sharif Z, Medalia A, Keefe RS, Harvey P, Bruder G, Barch DM, Choo T, Lee S, Lieberman JA.

J Clin Psychiatry. 2016 Jun;77(6):799-806. doi: 10.4088/JCP.15m09998.

PMID:
27035157
24.

A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys.

Smith EJ, Olson K, Haber LJ, Varghese B, Duramad P, Tustian AD, Oyejide A, Kirshner JR, Canova L, Menon J, Principio J, MacDonald D, Kantrowitz J, Papadopoulos N, Stahl N, Yancopoulos GD, Thurston G, Davis S.

Sci Rep. 2015 Dec 11;5:17943. doi: 10.1038/srep17943.

25.

Neural Substrates of Auditory Emotion Recognition Deficits in Schizophrenia.

Kantrowitz JT, Hoptman MJ, Leitman DI, Moreno-Ortega M, Lehrfeld JM, Dias E, Sehatpour P, Laukka P, Silipo G, Javitt DC.

J Neurosci. 2015 Nov 4;35(44):14909-21. doi: 10.1523/JNEUROSCI.4603-14.2015.

26.

Reflections on Becoming an Older and More Experienced Psychotherapist.

Kantrowitz JL.

J Clin Psychol. 2015 Nov;71(11):1093-103. doi: 10.1002/jclp.22219. Epub 2015 Sep 11.

PMID:
26361136
27.

D-serine for the treatment of negative symptoms in individuals at clinical high risk of schizophrenia: a pilot, double-blind, placebo-controlled, randomised parallel group mechanistic proof-of-concept trial.

Kantrowitz JT, Woods SW, Petkova E, Cornblatt B, Corcoran CM, Chen H, Silipo G, Javitt DC.

Lancet Psychiatry. 2015 May;2(5):403-412. doi: 10.1016/S2215-0366(15)00098-X. Epub 2015 Apr 28.

PMID:
26360284
28.

Single-dose ketamine followed by daily D-Cycloserine in treatment-resistant bipolar depression.

Kantrowitz JT, Halberstam B, Gangwisch J.

J Clin Psychiatry. 2015 Jun;76(6):737-8. doi: 10.4088/JCP.14l09527. No abstract available.

29.

The intra-aortic balloon pump: an early chapter in translational medicine.

Kantrowitz J.

Artif Organs. 2015 Jun;39(6):457-72. doi: 10.1111/aor.12536. No abstract available.

PMID:
26042476
30.

A Phase II study of a histamine H₃ receptor antagonist GSK239512 for cognitive impairment in stable schizophrenia subjects on antipsychotic therapy.

Jarskog LF, Lowy MT, Grove RA, Keefe RS, Horrigan JP, Ball MP, Breier A, Buchanan RW, Carter CS, Csernansky JG, Goff DC, Green MF, Kantrowitz JT, Keshavan MS, Laurelle M, Lieberman JA, Marder SR, Maruff P, McMahon RP, Seidman LJ, Peykamian MA.

Schizophr Res. 2015 May;164(1-3):136-42. doi: 10.1016/j.schres.2015.01.041. Epub 2015 Feb 24.

PMID:
25728831
31.

Auditory tasks for assessment of sensory function and affective prosody in schizophrenia.

Petkova E, Lu F, Kantrowitz J, Sanchez JL, Lehrfeld J, Scaramello N, Silipo G, DiCostanza J, Ross M, Su Z, Javitt DC, Butler PD.

Compr Psychiatry. 2014 Nov;55(8):1862-74. doi: 10.1016/j.comppsych.2014.08.046. Epub 2014 Aug 19.

32.

Amusia and protolanguage impairments in schizophrenia.

Kantrowitz JT, Scaramello N, Jakubovitz A, Lehrfeld JM, Laukka P, Elfenbein HA, Silipo G, Javitt DC.

Psychol Med. 2014 Oct;44(13):2739-48. doi: 10.1017/S0033291714000373. Epub 2014 Mar 31.

33.

Amotivation in schizophrenia: integrated assessment with behavioral, clinical, and imaging measures.

Wolf DH, Satterthwaite TD, Kantrowitz JJ, Katchmar N, Vandekar L, Elliott MA, Ruparel K.

Schizophr Bull. 2014 Nov;40(6):1328-37. doi: 10.1093/schbul/sbu026. Epub 2014 Mar 22.

34.

Glutamatergic abnormalities in schizophrenia: a review of proton MRS findings.

Poels EM, Kegeles LS, Kantrowitz JT, Javitt DC, Lieberman JA, Abi-Dargham A, Girgis RR.

Schizophr Res. 2014 Feb;152(2-3):325-32. doi: 10.1016/j.schres.2013.12.013. Epub 2014 Jan 11. Review.

35.

Imaging glutamate in schizophrenia: review of findings and implications for drug discovery.

Poels EM, Kegeles LS, Kantrowitz JT, Slifstein M, Javitt DC, Lieberman JA, Abi-Dargham A, Girgis RR.

Mol Psychiatry. 2014 Jan;19(1):20-9. doi: 10.1038/mp.2013.136. Epub 2013 Oct 29. Review.

PMID:
24166406
36.

The effect of postanalytic contact.

Kantrowitz JL.

J Am Psychoanal Assoc. 2013 Oct;61(5):947-56. doi: 10.1177/0003065113507110. No abstract available.

PMID:
24132967
37.

The 5% difference: early sensory processing predicts sarcasm perception in schizophrenia and schizo-affective disorder.

Kantrowitz JT, Hoptman MJ, Leitman DI, Silipo G, Javitt DC.

Psychol Med. 2014 Jan;44(1):25-36. doi: 10.1017/S0033291713000834. Epub 2013 Apr 24.

38.

Afterward: keeping analysis alive over time.

Kantrowitz JL.

Psychoanal Q. 2012 Oct;81(4):905-29. Review.

PMID:
23327002
39.

The 3rd Schizophrenia International Research Society Conference, 14-18 April 2012, Florence, Italy: summaries of oral sessions.

Abbs B, Achalia RM, Adelufosi AO, Aktener AY, Beveridge NJ, Bhakta SG, Blackman RK, Bora E, Byun MS, Cabanis M, Carrion R, Castellani CA, Chow TJ, Dmitrzak-Weglarz M, Gayer-Anderson C, Gomes FV, Haut K, Hori H, Kantrowitz JT, Kishimoto T, Lee FH, Lin A, Palaniyappan L, Quan M, Rubio MD, Ruiz de Azúa S, Sahoo S, Strauss GP, Szczepankiewicz A, Thompson AD, Trotta A, Tully LM, Uchida H, Velthorst E, Young JW, O'Shea A, Delisi LE.

Schizophr Res. 2012 Oct;141(1):e1-e24. doi: 10.1016/j.schres.2012.07.024. Epub 2012 Aug 19.

40.

Lurasidone for schizophrenia: what's different?

Kantrowitz JT, Citrome L.

Expert Rev Neurother. 2012 Mar;12(3):265-73. doi: 10.1586/ern.12.7. Review.

PMID:
22364325
41.

Auditory emotion recognition impairments in schizophrenia: relationship to acoustic features and cognition.

Gold R, Butler P, Revheim N, Leitman DI, Hansen JA, Gur RC, Kantrowitz JT, Laukka P, Juslin PN, Silipo GS, Javitt DC.

Am J Psychiatry. 2012 Apr;169(4):424-32. doi: 10.1176/appi.ajp.2011.11081230. Erratum in: Am J Psychiatry. 2012 Apr;169(4):439.

42.

Glutamatergic transmission in schizophrenia: from basic research to clinical practice.

Kantrowitz J, Javitt DC.

Curr Opin Psychiatry. 2012 Mar;25(2):96-102. doi: 10.1097/YCO.0b013e32835035b2. Review.

43.

Reduction in tonal discriminations predicts receptive emotion processing deficits in schizophrenia and schizoaffective disorder.

Kantrowitz JT, Leitman DI, Lehrfeld JM, Laukka P, Juslin PN, Butler PD, Silipo G, Javitt DC.

Schizophr Bull. 2013 Jan;39(1):86-93. doi: 10.1093/schbul/sbr060. Epub 2011 Jul 1.

44.

Schizoaffective disorder: a review of current research themes and pharmacological management.

Kantrowitz JT, Citrome L.

CNS Drugs. 2011 Apr;25(4):317-31. doi: 10.2165/11587630-000000000-00000. Review.

PMID:
21284405
45.

Psychoanalytic reflections through the prism of September 11, 2001.

Nunberg H, Dahl K, Herschkowitz S, Kantrowitz JL, Neubauer P, Orgel S, Basch S, Fogelman E; Psychoanalytic Research and Development Fund Inc.

Psychoanal Study Child. 2011;65:313-31.

PMID:
26027150
46.

Case studies and the therapeutic relationship.

Pies R, Kantrowitz JL.

Virtual Mentor. 2011 Jul 1;13(7):425-34. doi: 10.1001/virtualmentor.2011.13.7.ccas1-1107. No abstract available.

47.

Thinking glutamatergically: changing concepts of schizophrenia based upon changing neurochemical models.

Kantrowitz JT, Javitt DC.

Clin Schizophr Relat Psychoses. 2010 Oct;4(3):189-200. doi: 10.3371/CSRP.4.3.6. Review.

48.

High dose D-serine in the treatment of schizophrenia.

Kantrowitz JT, Malhotra AK, Cornblatt B, Silipo G, Balla A, Suckow RF, D'Souza C, Saksa J, Woods SW, Javitt DC.

Schizophr Res. 2010 Aug;121(1-3):125-30. doi: 10.1016/j.schres.2010.05.012. Epub 2010 Jun 11.

49.

The importance of a good night's sleep: an open-label trial of the sodium salt of gamma-hydroxybutyric acid in insomnia associated with schizophrenia.

Kantrowitz JT, Oakman E, Bickel S, Citrome L, Spielman A, Silipo G, Battaglia J, Javitt DC.

Schizophr Res. 2010 Jul;120(1-3):225-6. doi: 10.1016/j.schres.2010.03.035. No abstract available.

PMID:
20435443
50.

N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia?

Kantrowitz JT, Javitt DC.

Brain Res Bull. 2010 Sep 30;83(3-4):108-21. doi: 10.1016/j.brainresbull.2010.04.006. Epub 2010 Apr 24. Review.

Supplemental Content

Loading ...
Support Center